Drug Safety

, Volume 29, Issue 3, pp 209–230

Camptothecin and Podophyllotoxin Derivatives

Inhibitors of Topoisomerase I and II — Mechanisms of Action, Pharmacokinetics and Toxicity Profile
Review Article

Abstract

Camptothecins represent an established class of effective agents that selectively target topoisomerase I by trapping the catalytic intermediate of the topoisomerase I-DNA reaction, the cleavage complex. The water-soluble salt camptothecin-sodium — introduced in early trials in the 1960s — was highly toxic in animals, whereas the semisynthetic derivatives irinotecan and topotecan did not cause haemorrhagic cystitis because of their higher physicochemical stability and solubility at lower pH values. Myelosuppression, neutropenia and, to a lesser extent, thrombocytopenia are dose-limiting toxic effects of topotecan. In contrast to the structurally-related topotecan, irinotecan is a prodrug which has to be converted to SN-38, its active form. SN-38 is inactivated by conjugation, thus patients with Gilbert’s syndrome and other forms of genetic glucuronidation deficiency are at an increased risk of irinotecan-induced adverse effects, such as neutropenia and diarrhoea.

The cytotoxic mechanism of podophyllotoxin is the inhibition of topoisomerase II. Common adverse effects of etoposide include dose-limiting myelosuppression. Hypersensitivity reactions are more common with etoposide and teniposide than with etoposide phosphate because the formulations of the former contain sensitising solubilisers. Leukopenia and thrombocytopenia occur in 65% and 80%, respectively, of patients after administration of conventional doses of teniposide. Anorexia, vomiting and diarrhoea are generally of mild severity after administration of conventional doses of topoisomerase II inhibitors. Clinical pharmacokinetic studies have revealed substantial interindividual variabilities regarding the area under the concentration-time curve values and steady-state concentrations for all drugs reviewed in this article. Irinotecan, etoposide and teniposide are degraded via complex metabolic pathways. In contrast, topotecan primarily undergoes renal excretion. Regarding etoposide and teniposide, the extent of catechol formation over time during drug metabolism may be associated with a higher risk for secondary malignancies.

References

  1. 1.
    Malonne H, Atassi G. DNA topoisomerase targeting drugs: mechanisms of action and perspectives. Anticancer Drugs 1997; 8: 811–22PubMedCrossRefGoogle Scholar
  2. 2.
    Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res 1994; 54: 1431–9PubMedGoogle Scholar
  3. 3.
    Iyer L, Ratain MJ. Clinical pharmacology of camptothecins. Cancer Chemother Pharmacol 1998; 42Suppl.: S31–43PubMedCrossRefGoogle Scholar
  4. 4.
    Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002; 8: 641–61PubMedGoogle Scholar
  5. 5.
    Rothenberg ML. Topoisomerase I inhibitors: review and update. Ann Oncol 1997; 8: 837–55PubMedCrossRefGoogle Scholar
  6. 6.
    Husain I, Mohler JL, Seigler HF, et al. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 1994; 54: 539–46PubMedGoogle Scholar
  7. 7.
    Burris HA, Rothenberg ML, Kuhn JG, et al. Clinical trials with the topoisomerase I inhibitors. Semin Oncol 1992; 19: 663–9PubMedGoogle Scholar
  8. 8.
    Gupta E, Mick R, Ramirez J, et al. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 1997; 15: 1502–10PubMedGoogle Scholar
  9. 9.
    Loos WJ, Gelderblom HJ, Verweij J, et al. Gender-dependent pharmacokinetics of topotecan in adult patients. Anticancer Drugs 2000; 11: 673–80PubMedCrossRefGoogle Scholar
  10. 10.
    Herben VM, ten Bokkel Huinink WW, Beijnen JH. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 1996; 31: 85–102PubMedCrossRefGoogle Scholar
  11. 11.
    Levy T, Inbar M, Menczer J, et al. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol Oncol 2004; 95: 686–90PubMedCrossRefGoogle Scholar
  12. 12.
    Herben VM, Schoemaker E, Rosing H, et al. Urinary and fecal excretion of topotecan in patients with malignant solid tumours. Cancer Chemother Pharmacol 2002; 50: 59–64PubMedCrossRefGoogle Scholar
  13. 13.
    Loos WJ, Gelderblom H, Verweij J, et al. Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis. Anticancer Drugs 2003; 14: 227–32PubMedCrossRefGoogle Scholar
  14. 14.
    O’Reilly S. Topotecan: what dose, what schedule, what route? Clin Cancer Res 1999; 5: 3–5PubMedGoogle Scholar
  15. 15.
    O’Reilly S, Rowinsky EK, Slichenmyer W, et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 1996; 14: 3062–73PubMedGoogle Scholar
  16. 16.
    Montazeri A, Culine S, Laguerre B, et al. Individual adaptive dosing of topotecan in ovarian cancer. Clin Cancer Res 2002; 8: 394–9PubMedGoogle Scholar
  17. 17.
    Herrington JD, Figueroa JA, Kirstein MN, et al. Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction. Cancer Chemother Pharmacol 2001; 47: 89–93PubMedCrossRefGoogle Scholar
  18. 18.
    Dennis MJ, Beijnen JH, Grochow LB, et al. An overview of the clinical pharmacology of topotecan. Semin Oncol 1997; 24: S5–18PubMedGoogle Scholar
  19. 19.
    Blaney SM, Heideman R, Berg S, et al. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol 2003; 21: 143–7PubMedCrossRefGoogle Scholar
  20. 20.
    Blaney SM, Cole DE, Godwin K, et al. Intrathecal administration of topotecan in nonhuman primates. Cancer Chemother Pharmacol 1995; 36: 121–4PubMedCrossRefGoogle Scholar
  21. 21.
    Kollmannsberger C, Mross K, Jakob A, et al. Topotecan: a novel topoisomerase I inhibitor. Pharmacology and clinical experience. Oncology 1999; 56: 1–12PubMedCrossRefGoogle Scholar
  22. 22.
    Rowinsky EK, Kaufmann SH, Baker SD, et al. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 1996; 14: 3074–84PubMedGoogle Scholar
  23. 23.
    Breidenbach M, Rein DT, Schondorf T, et al. Hematological side-effect profiles of individualized chemotherapy regimen for recurrent ovarian cancer. Anticancer Drugs 2003; 14: 341–6PubMedCrossRefGoogle Scholar
  24. 24.
    Saltz L, Sirott M, Young C, et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 1993; 85: 1499–507PubMedCrossRefGoogle Scholar
  25. 25.
    Rowinsky EK, Grochow LB, Sartorius SE, et al. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. J Clin Oncol 1996; 14: 1224–35PubMedGoogle Scholar
  26. 26.
    von Pawel J, Gatzemeier U, Pujol JL, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001; 19: 1743–9Google Scholar
  27. 27.
    Creemers GJ, Gerrits CJ, Eckardt JR, et al. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol 1997; 15: 1087–93PubMedGoogle Scholar
  28. 28.
    Gore M, Oza A, Rustin G, et al. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer 2002; 38: 57–63PubMedCrossRefGoogle Scholar
  29. 29.
    Saigi E, Salut A, Campos JM, et al. Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200 mg/m2) according to toxicity prognostic factors. Anticancer Drugs 2004; 15: 835–41PubMedCrossRefGoogle Scholar
  30. 30.
    Hofheinz R, Hartung G, Samel S, et al. Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer: a phase II study. Anticancer Drugs 2002; 13: 999–1004PubMedCrossRefGoogle Scholar
  31. 31.
    Sanghani SP, Quinney SK, Fredenburg TB, et al. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab Dispos 2004; 32: 505–11PubMedCrossRefGoogle Scholar
  32. 32.
    Cersosimo RJ. Irinotecan: a new antineoplastic agent for the management of colorectal cancer. Ann Pharmacother 1998; 32: 1324–33PubMedCrossRefGoogle Scholar
  33. 33.
    Carlini LE, Meropol NJ, Bever J, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 2005; 11: 1226–36PubMedGoogle Scholar
  34. 34.
    Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11): role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101: 847–54PubMedCrossRefGoogle Scholar
  35. 35.
    Kraemer D, Scheurlen M. Gilbert disease and type I and II Crigler-Najjar syndrome due to mutations in the same UGT1A1 gene locus [in German]. Med Klin (Munich) 2002; 97: 528–32CrossRefGoogle Scholar
  36. 36.
    Innocenti F, Undevia SD, Iyer L, et al. UGT1A1*28 polymorphism is a predictor of neutropenia in irinotecan chemotherapy [abstract 495]. Proc Am Soc Clin Oncol 2003; 22: 124Google Scholar
  37. 37.
    Ando Y, Saka H, Asai G, et al. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol 1998; 9: 845–7PubMedCrossRefGoogle Scholar
  38. 38.
    Innocenti F, Iyer L, Ratain MJ. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab Dispos 2001; 29: 596–600PubMedGoogle Scholar
  39. 39.
    Crews KR, Stewart CF, Jones-Wallace D, et al. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res 2002; 8: 2202–9PubMedGoogle Scholar
  40. 40.
    Murry DJ, Cherrick I, Salama V, et al. Influence of phenytoin on the disposition of irinotecan: a case report. J Pediatr Hematol Oncol 2002; 24: 130–3PubMedCrossRefGoogle Scholar
  41. 41.
    Sanghani SP, Quinney SK, Fredenburg TB, et al. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab Dispos 2004; 32: 505–11PubMedCrossRefGoogle Scholar
  42. 42.
    Yamamoto W, Verweij J, de Bruijn P, et al. Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells. Anticancer Drugs 2001; 12: 419–32PubMedCrossRefGoogle Scholar
  43. 43.
    Chester JD, Joel SP, Cheeseman SL, et al. Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer. J Clin Oncol 2003; 21: 1125–32PubMedCrossRefGoogle Scholar
  44. 44.
    Takasuna K, Hagiwara T, Hirohashi M, et al. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother Pharmacol 1998; 42: 280–6PubMedCrossRefGoogle Scholar
  45. 45.
    Abigerges D, Chabot CG, Armand J-P, et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995; 13: 210–21PubMedGoogle Scholar
  46. 46.
    Alimonti A, Satta F, Pavese I, et al. Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer. Ann Oncol 2003; 14: 805–6PubMedCrossRefGoogle Scholar
  47. 47.
    Lokiec F, Canal P, Gay C, et al. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother Pharmacol 1995; 36: 79–82PubMedCrossRefGoogle Scholar
  48. 48.
    Ratain MJ. Insights into the pharmacokinetics and pharmacodynamics of irinotecan. Clin Cancer Res 2000; 6: 3393–4PubMedGoogle Scholar
  49. 49.
    Santos A, Zanetta S, Cresteil T, et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 2000; 6: 2012–20PubMedGoogle Scholar
  50. 50.
    Mathijssen RH, Verweij J, de Bruijn P, et al. Effects of St. John’s wort on irinotecan metabolism. J Natl Cancer Inst 2002; 94: 1247–9PubMedCrossRefGoogle Scholar
  51. 51.
    Sai K, Kaniwa N, Ozawa S, et al. A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4. Drug Metab Dispos 2001; 29: 1505–13PubMedGoogle Scholar
  52. 52.
    Slatter JG, Schaaf LJ, Sams JP, et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos 2000; 28: 423–33PubMedGoogle Scholar
  53. 53.
    Sparreboom A, de Jonge MJ, de Bruijn P, et al. Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res 1998; 4: 2747–54PubMedGoogle Scholar
  54. 54.
    Van Groeningen CJ, van der Vijgh WJ, Baars JJ, et al. Altered pharmacokinetics and metabolism of CPT-11 in liver dysfunction: a need for guidelines. Clin Cancer Res 2000; 6: 1342–6PubMedGoogle Scholar
  55. 55.
    Venook AP, Enders KC, Fleming G, et al. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol 2003; 14: 1783–90PubMedCrossRefGoogle Scholar
  56. 56.
    Ong SY, Clarke SJ, Bishop J, et al. Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction. Anticancer Drugs 2001; 12: 619–25PubMedCrossRefGoogle Scholar
  57. 57.
    Raymond E, Boige V, Faivre S, et al. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol 2002; 20: 4303–12PubMedCrossRefGoogle Scholar
  58. 58.
    Gandia D, Abigerges D, Armand JP, et al. CPT-11-induced cholinergic effects in cancer patients. J Clin Oncol 1993; 11: 196–7PubMedGoogle Scholar
  59. 59.
    Saliba F, Hagipantelli R, Misset JL, et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol 1998; 16: 2745–51PubMedGoogle Scholar
  60. 60.
    Dodds HM, Bishop JF, Rivory LP. More about: irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin. J Natl Cancer Inst 1999; 91: 91–2PubMedCrossRefGoogle Scholar
  61. 61.
    Wasserman E, Cuvier C, Lokiec F, et al. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol 1999; 17: 1751–9PubMedGoogle Scholar
  62. 62.
    Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 2002; 13: 1841–51PubMedCrossRefGoogle Scholar
  63. 63.
    Castellanos C, Aldaz A, Zufia L, et al. Biliary index accurately predict the severity of irinotecan (CPT-11) induced delayed diarrhea in colo-rectal cancer patients [abstract 648]. Proc Am Soc Clin Oncol 2003; 22: 162Google Scholar
  64. 64.
    Fittkau M, Voigt W, Holzhausen HJ, et al. Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats. J Cancer Res Clin Oncol 2004; 130: 388–94PubMedCrossRefGoogle Scholar
  65. 65.
    Kehrer DF, Sparreboom A, Verweij J, et al. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 2001; 7: 1136–41PubMedGoogle Scholar
  66. 66.
    Hennebelle I, Terret C, Chatelut E, et al. Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activity. Anticancer Drugs 2000; 11: 465–70PubMedCrossRefGoogle Scholar
  67. 67.
    Takeda Y, Kobayashi K, Akiyama Y, et al. Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients. Int J Cancer 2001; 92: 269–75PubMedCrossRefGoogle Scholar
  68. 68.
    Ikegami T, Ha L, Arimori K, et al. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea. Cancer Res 2002; 62: 179–87PubMedGoogle Scholar
  69. 69.
    Prado D. A multinational comparison of racecadotril and loperamide in the treatment of acute watery diarrhoea in adults. Scand J Gastroenterol 2002; 37(6): 656–62PubMedCrossRefGoogle Scholar
  70. 70.
    Ukropec J, Pro B, Lozano R, et al. Refractory CPT-11 induced diarrhea in cancer patients: resolution with octreotide, four case studies [abstract]. Proc Am Soc Clin Oncol 2002; 21: 2904Google Scholar
  71. 71.
    Benson AB, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004; 22: 2918–26PubMedCrossRefGoogle Scholar
  72. 72.
    Barbounis V, Koumakis G, Vassilomanolakis M, et al. Control of irinotecan-induced diarrhea by octreotide after loperamide failure. Support Care Cancer 2001; 9: 258–60PubMedCrossRefGoogle Scholar
  73. 73.
    Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 2001; 40: 723–51PubMedCrossRefGoogle Scholar
  74. 74.
    Lenfers BH, Loeffler TM, Droege CM, et al. Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. Ann Oncol 1999; 10(10): 1251–3PubMedCrossRefGoogle Scholar
  75. 75.
    Karthaus M, Ballo H, Steinmetz T, et al. Budesonide for prevention of irinotecan (CPT-11)-induced diarrhea: results of a double-blind, placebo-controlled, multicenter, randomized phase-III-study in patients with advanced colorectal cancer (CRC) [abstract 2935]. Proc Am Soc Clin Oncol 2003; 22: 730Google Scholar
  76. 76.
    Sharma R, Tobin P. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol 2005; 9: 93–102CrossRefGoogle Scholar
  77. 77.
    Michael M, Brittain M, Nagai J, et al. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. J Clin Oncol 2004; 22: 4410–7PubMedCrossRefGoogle Scholar
  78. 78.
    Mansky PJ, Straus SE. St John’s Wort: more implications for cancer patients. J Natl Cancer Inst 2002; 94: 1187–8PubMedCrossRefGoogle Scholar
  79. 79.
    Mathijssen RH, Sparreboom A, Dumez H, et al. Altered irinotecan metabolism in a patient receiving phenytoin. Anticancer Drugs 2002; 13: 139–40PubMedCrossRefGoogle Scholar
  80. 80.
    Kehrer DF, Mathijssen RH, Verweij J, et al. Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 2002; 20: 3122–9PubMedCrossRefGoogle Scholar
  81. 81.
    Minami H, Fujii H, Igarashi T, et al. Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks. Clin Cancer Res 2001; 7: 3056–64PubMedGoogle Scholar
  82. 82.
    Mitsui I, Kumazawa E, Hirota Y, et al. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res 1995; 86: 776–82PubMedCrossRefGoogle Scholar
  83. 83.
    Kajimura T. DX-8951f: single intravenous dose toxicity study in dogs. In house study report (8951 J-TOXO 19). Tokyo, Japan: Daiichi Pharmaceutical Co. Ltd; 1996Google Scholar
  84. 84.
    Braybrooke JP, Boven E, Bates NP, et al. Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies. Ann Oncol 2003; 14: 913–21PubMedCrossRefGoogle Scholar
  85. 85.
    Rowinsky EK, Johnson TR, Geyer CE, et al. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol 2000; 18: 3151–63PubMedGoogle Scholar
  86. 86.
    Jung LL, Ramanathan RK, Egorin MJ, et al. Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors. Cancer Chemother Pharmacol 2004; 54: 487–96PubMedCrossRefGoogle Scholar
  87. 87.
    Bailly C. Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs. Crit Rev Oncol Hematol 2003; 45: 91–108PubMedCrossRefGoogle Scholar
  88. 88.
    de Jonge MJ, Verweij J, Loos WJ, et al. Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva. Clin Pharmacol Ther 1999; 65: 491–9PubMedCrossRefGoogle Scholar
  89. 89.
    Ellerhorst JA, Bedikian AY, Smith TM, et al. Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma. Anticancer Drugs 2002; 13: 169–72PubMedCrossRefGoogle Scholar
  90. 90.
    Rowinsky EK, Rizzo J, Ochoa L, et al. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. J Clin Oncol 2003; 21: 148–57PubMedCrossRefGoogle Scholar
  91. 91.
    Saetern AM, Brandl M, Bakkelund WH, et al. Cytotoxic effect of different camptothecin formulations on human colon carcinoma in vitro. Anticancer Drugs 2004; 15: 899–906PubMedCrossRefGoogle Scholar
  92. 92.
    Henwood JM, Brogden RN. Etoposide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs 1990; 39: 438–90PubMedCrossRefGoogle Scholar
  93. 93.
    Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998; 34: 1514–21PubMedCrossRefGoogle Scholar
  94. 94.
    Hande KR. Topoisomerase II inhibitors. In: Giaccone G, Schilsky RL, Sondel P, editors. Cancer chemotherapy and biological response modifiers. Amsterdam: Elsevier, 2003: 103–25CrossRefGoogle Scholar
  95. 95.
    Lipp H-P. Prevention and management of anticancer drug toxicity: the significance of clinical pharmacokinetics [thesis]. Jena: University of Jena, 1995Google Scholar
  96. 96.
    Hussain M, Vaishampayan U, Heilbrun LK, et al. A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer. Invest New Drugs 2003; 21: 465–71PubMedCrossRefGoogle Scholar
  97. 97.
    Fortune JM, Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 2000; 64: 221–53PubMedCrossRefGoogle Scholar
  98. 98.
    Clark PI, Slevin ML. The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet 1987; 12: 223–52PubMedCrossRefGoogle Scholar
  99. 99.
    Long BH. Mechanisms of action of teniposide (VM-26) and comparison with etoposide (VP-16). Semin Oncol 1992; 19: 3–19PubMedGoogle Scholar
  100. 100.
    Budman DR, Igwemezie LN, Kaul S, et al. Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors. J Clin Oncol 1994; 12: 1902–9PubMedGoogle Scholar
  101. 101.
    Reif S, Kingreen D, Kloft C, et al. Bioequivalence investigation of high-dose etoposide and etoposide phosphate in lymphoma patients. Cancer Chemother Pharmacol 2001; 48: 134–40PubMedCrossRefGoogle Scholar
  102. 102.
    Schacter LP, Igwemezie LN, Seyedsadr M, et al. Clinical and pharmacokinetic overview of parenteral etoposide phosphate. Cancer Chemother Pharmacol 1994; 34Suppl.: S58–63PubMedCrossRefGoogle Scholar
  103. 103.
    Kaul S, Igwemezie LN, Stewart DJ, et al. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors. J Clin Oncol 1995; 13: 2835–41PubMedGoogle Scholar
  104. 104.
    Harvey VJ, Slevin ML, Joel SP, et al. The effect of dose on the bioavailability of oral etoposide. Cancer Chemother Pharmacol 1986; 16: 178–81PubMedCrossRefGoogle Scholar
  105. 105.
    Hande KR, Krozely MG, Greco FA, et al. Bioavailability of low-dose oral etoposide. J Clin Oncol 1993; 11: 374–7PubMedGoogle Scholar
  106. 106.
    Aita P, Robieux I, Sorio R, et al. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. Cancer Chemother Pharmacol 1999; 43: 287–94PubMedCrossRefGoogle Scholar
  107. 107.
    Millward MJ, Newell DR, Yuen K, et al. Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer. Cancer Chemother Pharmacol 1995; 37: 161–7PubMedCrossRefGoogle Scholar
  108. 108.
    Chabot GG, Armand JP, Terret C, et al. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. J Clin Oncol 1996; 14: 2020–30PubMedGoogle Scholar
  109. 109.
    De Jong RS, Slijfer EAM, Uges DRA, et al. Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile. Br J Cancer 1997; 76: 1480–3PubMedCrossRefGoogle Scholar
  110. 110.
    Edick MJ, Gajjar A, Mahmoud HH, et al. Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. J Clin Oncol 2003; 21: 1340–6PubMedCrossRefGoogle Scholar
  111. 111.
    Toffoli G, Corona G, Basso B, et al. Pharmacokinetic optimisation of treatment with oral etoposide. Clin Pharmacokinet 2004; 43: 441–66PubMedCrossRefGoogle Scholar
  112. 112.
    Joel SP, Shah R, Slevin ML. Etoposide dosage and pharmacodynamics. Cancer Chemother Pharmacol 1994; 34Suppl.: S69–75PubMedCrossRefGoogle Scholar
  113. 113.
    Joel S. The clinical pharmacology of etoposide: an update. Cancer Treat Rev 1996; 22: 179–221PubMedCrossRefGoogle Scholar
  114. 114.
    Liu B, Earl HM, Poole CJ, et al. Etoposide protein binding in cancer patients. Cancer Chemother Pharmacol 1995; 36: 506–12PubMedCrossRefGoogle Scholar
  115. 115.
    Nguyen L, Chatelut E, Chevreau C, et al. Population pharmacokinetics of total and unbound etoposide. Cancer Chemother Pharmacol 1998; 41: 125–32PubMedCrossRefGoogle Scholar
  116. 116.
    D’Incalci M, Rossi C, Zucchetti M, et al. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res 1986; 46: 2566–71PubMedGoogle Scholar
  117. 117.
    Stewart CF, Arbuck SG, Fleming RA, et al. Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. J Clin Oncol 1990; 8: 1874–9PubMedGoogle Scholar
  118. 118.
    Schwinghammer TL, Fleming RA, Rosenfeld CS, et al. Disposition of total and unbound etoposide following high-dose therapy. Cancer Chemother Pharmacol 1993; 32: 273–8PubMedCrossRefGoogle Scholar
  119. 119.
    Mross K, Bewermeier P, Kruger W, et al. Pharmacokinetics of undiluted or diluted high-dose etoposide with or without busulfan administered to patients with hematologic malignancies. J Clin Oncol 1994; 12: 1468–74PubMedGoogle Scholar
  120. 120.
    Kreis W, Budman DR, Vinciguerra V, et al. Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors. Cancer Chemother Pharmacol 1996; 38: 378–84PubMedCrossRefGoogle Scholar
  121. 121.
    Zhuo X, Zheng N, Felix CA, et al. Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos 2004; 32: 993–1000PubMedGoogle Scholar
  122. 122.
    Relling MV, Nemec J, Schuetz EG, et al. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 1994; 45: 352–8PubMedGoogle Scholar
  123. 123.
    Hainsworth JD, Greco FA. Etoposide: twenty years later. Ann Oncol 1995; 6: 325–41PubMedGoogle Scholar
  124. 124.
    Hande KR, Wolff SN, Greco FA, et al. Etoposide kinetics in patients with obstructive jaundice. J Clin Oncol 1990; 8: 1101–7PubMedGoogle Scholar
  125. 125.
    Holthuis JJ, Van de Vyver FL, van Oort WJ, et al. Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient. Cancer Treat Rep 1985; 69: 1279–82PubMedGoogle Scholar
  126. 126.
    Kiya K, Uozumi T, Ogasawara H, et al. Penetration of etoposide into human malignant brain tumors after intravenous and oral administration. Cancer Chemother Pharmacol 1992; 29: 339–42PubMedCrossRefGoogle Scholar
  127. 127.
    van der GA, Sonneveld P, Mans DR, et al. Intrathecal administration of etoposide in the treatment of malignant meningitis: feasibility and pharmacokinetic data. Cancer Chemother Pharmacol 1992; 29: 335–7CrossRefGoogle Scholar
  128. 128.
    Hande K, Messenger M, Wagner J, et al. Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration. Clin Cancer Res 1999; 5: 2742–7PubMedGoogle Scholar
  129. 129.
    Minami H, Ratain MJ, Ando Y, et al. Pharmacodynamic modeling of prolonged administration of etoposide. Cancer Chemother Pharmacol 1996; 39: 61–6PubMedCrossRefGoogle Scholar
  130. 130.
    Brooks DJ, Srinivas NR, Alberts DS, et al. Phase I and pharmacokinetic study of etoposide phosphate. Anticancer Drugs 1995; 6: 637–44PubMedCrossRefGoogle Scholar
  131. 131.
    Issell BF. The podophyllotoxin derivatives VP16-213 and VM26. Cancer Chemother Pharmacol 1982; 7(2-3): 73–80PubMedGoogle Scholar
  132. 132.
    Weiss RB. Hypersensitivity reactions. Semin Oncol 1992; 19: 458–77PubMedGoogle Scholar
  133. 133.
    Alley E, Green R, Schuchter L. Cutaneous toxicities of cancer therapy. Curr Opin Oncol 2002; 14: 212–6PubMedCrossRefGoogle Scholar
  134. 134.
    Hudson MM, Weinstein HJ, Donaldson SS, et al. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin’s disease. J Clin Oncol 1993; 11: 1080–4PubMedGoogle Scholar
  135. 135.
    Ogle KM, Kennedy BJ. Hypersensitivity reactions to etoposide: a case report and review of the literature. Am J Clin Oncol 1988; 11: 663–5PubMedCrossRefGoogle Scholar
  136. 136.
    Jameson CH, Solanki DL. Stevens-Johnson syndrome associated with etoposide therapy. Cancer Treat Rep 1983; 67: 1050–1PubMedGoogle Scholar
  137. 137.
    Hoetelmans RM, Schornagel JH, Bokkel Huinink WW, et al. Hypersensitivity reactions to etoposide. Ann Pharmacother 1996; 30: 367–71PubMedGoogle Scholar
  138. 138.
    Nolte H, Carstensen H, Hertz H. VM-26 (teniposide)-induced hypersensitivity and degranulation of basophils in children. Am J Pediatr Hematol Oncol 1988; 10: 308–12PubMedCrossRefGoogle Scholar
  139. 139.
    Siderov J, Prasad P, De Boer R, et al. Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide. Br J Cancer 2002; 86: 12–3PubMedCrossRefGoogle Scholar
  140. 140.
    Bernstein BJ, Troner MB. Successful rechallenge with etoposide phosphate after an acute hypersensitivity reaction to etoposide. Pharmacotherapy 1999; 19: 989–91PubMedCrossRefGoogle Scholar
  141. 141.
    Cersosimo RJ, Calarese P, Karp DD. Acute hypotensive reaction to etoposide with successful rechallenge: case report and review of the literature. DICP 1989; 23: 876–7PubMedGoogle Scholar
  142. 142.
    Wilson DB, Beck TM, Gundlach CA. Paclitaxel formulation as a cause of ethanol intoxication. Ann Pharmacother 1997; 31: 873–5PubMedGoogle Scholar
  143. 143.
    Imrie KR, Couture F, Turner CC, et al. Peripheral neuropathy following high-dose etoposide and autologous bone marrow transplantation. Bone Marrow Transplant 1994; 13: 77–9PubMedGoogle Scholar
  144. 144.
    McLeod HL, Baker DK, Pui CH, et al. Somnolence, hypotension, and metabolic acidosis following high-dose teniposide treatment in children with leukemia. Cancer Chemother Pharmacol 1991; 29: 150–4PubMedCrossRefGoogle Scholar
  145. 145.
    Nakanomyo H, Hiraoka M, Shiraya M. Mutagenicity tests of etoposide and teniposide [in Japanese]. J Toxicol Sci 1986; 11Suppl. 1: 301–10PubMedCrossRefGoogle Scholar
  146. 146.
    Anderson RD, Berger NA. International Commission for Protection Against Environmental Mutagens and Carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents. Mutat Res 1994; 309: 109–42PubMedCrossRefGoogle Scholar
  147. 147.
    Kollmannsberger C, Beyer J, Droz JP, et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 1998; 16: 3386–91PubMedGoogle Scholar
  148. 148.
    Duffner PK, Krischer JP, Horowitz ME, et al. Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study. Ann Neurol 1998; 44: 313–6PubMedCrossRefGoogle Scholar
  149. 149.
    Horibe K, Matsushita T, Numata S, et al. Acute promyelocytic leukemia with t(15;17) abnormality after chemotherapy containing etoposide for Langerhans cell histiocytosis. Cancer 1993; 72: 3723–6PubMedCrossRefGoogle Scholar
  150. 150.
    Relling MV, Yanishevski Y, Nemec J, et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 1998; 12: 346–52PubMedCrossRefGoogle Scholar
  151. 151.
    Zulian GB, Selby P, Milan S, et al. High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin’s disease. Br J Cancer 1989; 59: 631–5PubMedCrossRefGoogle Scholar
  152. 152.
    Stine KC, Saylors RL, Sawyer JR, et al. Secondary acute myelogenous leukemia following safe exposure to etoposide. J Clin Oncol 1997; 15: 1583–6PubMedGoogle Scholar
  153. 153.
    Houck W, Einhorn LH. Secondary leukemias in germ cell tumor patients undergoing autologous stem cell transplant utilizing high dose etoposide [abstract 1566]. Proc Am Soc Clin Oncol 2003; 22: 390CrossRefGoogle Scholar
  154. 154.
    Ratain MJ, Kaminer LS, Bitran JD, et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood 1987; 70: 1412–7PubMedGoogle Scholar
  155. 155.
    Pui CH, Relling MV. Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol 2000; 109: 13–23PubMedCrossRefGoogle Scholar
  156. 156.
    Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991; 325: 1682–7PubMedCrossRefGoogle Scholar
  157. 157.
    Mistry AR, Felix CA, Whitmarsh RJ, et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005; 352: 1529–38PubMedCrossRefGoogle Scholar
  158. 158.
    Le Deley MC, Leblanc T, Shamsaldin A, et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Societe Francaise d’Oncologie Pediatrique. J Clin Oncol 2003; 21: 1074–81PubMedCrossRefGoogle Scholar
  159. 159.
    Sandler ES, Friedman DJ, Mustafa MM, et al. Treatment of children with epipodophyllotoxin-induced secondary acute myeloid leukemia. Cancer 1997; 79: 1049–54PubMedCrossRefGoogle Scholar
  160. 160.
    Rodman JH, Abromowitch M, Sinkule JA, et al. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial. J Clin Oncol 1987; 5: 1007–14PubMedGoogle Scholar
  161. 161.
    Lum BL, Kaubisch S, Yahanda AM, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992; 10: 1635–42PubMedGoogle Scholar
  162. 162.
    Baker DK, Relling MV, Pui CH, et al. Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol 1992; 10: 311–5PubMedGoogle Scholar
  163. 163.
    Splinter TA, Holthuis JJ, Kok TC, et al. Absolute bioavailability and pharmacokinetics of oral teniposide. Semin Oncol 1992; 19: 28–34PubMedGoogle Scholar
  164. 164.
    Bork E, Hansen M, Dombernowsky P, et al. Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer: results of a phase II trial in untreated patients. J Clin Oncol 1986; 4: 524–7PubMedGoogle Scholar
  165. 165.
    Whitacre CM, Zborowska E, Gordon NH, et al. Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res 1997; 57: 1425–8PubMedGoogle Scholar
  166. 166.
    Bonner JA, Kozelsky TF. The significance of the sequence of administration of topotecan and etoposide. Cancer Chemother Pharmacol 1996; 39: 109–12PubMedCrossRefGoogle Scholar
  167. 167.
    Dowlati A, Levitan N, Gordon NH, et al. Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2001; 47: 141–8PubMedCrossRefGoogle Scholar
  168. 168.
    Hammond LA, Eckardt JR, Ganapathi R, et al. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide. Clin Cancer Res 1998; 4: 1459–67PubMedGoogle Scholar
  169. 169.
    van Gijn R, Bokkel Huinink WW, Rodenhuis S, et al. Topoisomerase I/II inhibitor intoplicine administered as a 24h infusion: phase I and pharmacologic study. Anticancer Drugs 1999; 10: 17–23PubMedCrossRefGoogle Scholar
  170. 170.
    Etievant C, Kruczynski A, Barret JM, et al. F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103. Cancer Chemother Pharmacol 2000; 46: 101–13PubMedCrossRefGoogle Scholar
  171. 171.
    Caponigro F, Dittrich C, Sorensen JB, et al. Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer. Eur J Cancer 2002; 38: 70–4PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Department of Oncology/Hematology/Immunology/Pneumology/RheumatologyEberhard Karls University Tübingen, UKT - Medical Center IITübingenGermany
  2. 2.Department of Clinical PharmacyEberhard-Karls-University TübingenTübingenGermany

Personalised recommendations